![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.25 | 0.63% | 40.11 | 6,472 | 12:11:40 |
GSK begins shipping FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research.
GSK expects to distribute over 50 million doses of its influenza vaccine to the US market, continuing to support annual immunization across the US. Despite increased large-scale public health efforts in the 2021-2022 flu season, vaccination rates were similar to the 2020-2021 season. The US Centers for Disease Control and Prevention (CDC) data from April 2022 also showed significant disparities in vaccination coverage for many age groups and ethnicities.1
“The COVID-19 pandemic has shone a light on health disparities in the US and that there is still much more to be done to close the gap. GSK is committed to working alongside our public health partners to increase education and awareness about annual flu vaccination across the board, but especially in underserved communities of color,” said Temi Folaranmi, Vice President and Vaccines Therapeutic Area Head, US Medical Affairs, GSK.
Both FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT will be available in a 0.5mL, single-dose, pre-filled syringe, and are indicated for patients six months and older in line with CDC recommendations.
CDC recommends an annual flu vaccination for anyone aged six months and older who do not have contraindications. According to CDC, annual influenza vaccinations are the best way to help protect against the flu.2
For egg-based influenza vaccines for the 2022-23 flu season, the World Health Organization and FDA’s Vaccines and Related Biological Products Advisory Committee recommended including an A/Victoria/2570/2019 (H1N1) pdm09-like virus, an A/Darwin/9/2021 (H3N2)-like virus, a B/Austria/1359417/2021 (B/Victoria lineage)-like virus and a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.3
About Influenza
The flu (influenza) is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness, and at times can lead to death. The best way to prevent flu is by getting a flu vaccine each year.2
Anyone can get the flu, however, it can be serious for young children, adults 65 years and older, pregnant women and people with pre-existing chronic health conditions, such as asthma.2
For more information about the flu, visit https://us.gsk.com/en-us/about-us/vaccines/flu.
Indication for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT
FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccines. FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are approved for use in persons aged 6 months and older.
Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT
Please see full Prescribing Information for FLUARIX QUADRIVALENT and for FLULAVAL QUADRIVALENT.
About GSK
GSK is a science-led global healthcare company. For further information please visit https://www.gsk.com/en-gb/about-us/.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q1 Results for 2022 and any impacts of the COVID-19 pandemic.
Registered in England & Wales: No. 3888792
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS
References
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005842/en/
Media inquiries: Kathleen Quinn +1 202 603 5003 (Washington DC) Sean Clements +1 215 740 3088 (Philadelphia) Alison Hunt +1 540 742 3391 (Washington DC)
Analyst/Investor inquiries: Nick Stone +44 (0) 7717 618834 (London) Sonya Ghobrial +44 (0) 7392 784784 (Consumer) James Dodwell +44 (0) 20 8047 2406 (London) Mick Readey +44 (0) 7990 339653 (London) Josh Williams +44 (0) 7385 415719 (London) Jeff McLaughlin +1 215 751 7002 (Philadelphia)
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions